A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Completed
Phase 1

Conditions

Healthy Participants

Treatments

Drug: Famotidine
Drug: BMS-986256

Study type

Interventional

Funder types

Industry

Identifiers

NCT04941755
IM026-029

Details and patient eligibility

About

The purpose of this study is to investigate the effect of gastric pH changes induced by famotidine on the drug levels of BMS-986256.

Enrollment

22 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy participants, defined as having no clinically significant deviations from normal in medical history
  • Weight ≥ 50 kg and body mass index between 18.0 kg/m2 and 32.0 kg/m2, inclusive, at screening
  • Normal renal function at screening

Exclusion criteria

  • Any significant acute or chronic medical illness
  • Current or recent gastrointestinal (GI) disease that could impact upon the absorption of study treatment
  • Any major surgery within 4 weeks of study treatment administration
  • Significant history of GI abnormalities

Other protocol-defined inclusion/exclusion criteria apply

Trial design

22 participants in 2 patient groups

Sequence AB
Experimental group
Treatment:
Drug: BMS-986256
Drug: Famotidine
Sequence BA
Experimental group
Treatment:
Drug: BMS-986256
Drug: Famotidine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems